News Image

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Provided By GlobeNewswire

Last update: Jun 9, 2025

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe

Read more at globenewswire.com

PDS BIOTECHNOLOGY CORP

NASDAQ:PDSB (11/26/2025, 8:00:00 PM)

After market: 0.8151 +0 (+0.22%)

0.8133

+0.07 (+9.08%)



Find more stocks in the Stock Screener

PDSB Latest News and Analysis

Follow ChartMill for more